Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 1085-1095

  Ju, Rui ^a   Wu, Danwei ^a   Guo, Lei ^a   Li, Juan ^a   Ye, Caiying ^a   Zhang, Dechang ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Carboxyamidotriazole; Dexamethasone; Inflammatory cytokine; Tumour associated macrophages

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; CYTOKINE; DEXAMETHASONE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTHRITIS, EXPERIMENTAL; CARCINOMA, LEWIS LUNG; COCULTURE TECHNIQUES; CYTOKINES; DEXAMETHASONE; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RATS, WISTAR; TRIAZOLES; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859487873     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.050     Document Type: Article

References (54)

1. W.J. Wasilenko, A.J. Palad, and K.D. Somers Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines Int J Cancer 68 1996 259 264
2. P.A. Lambert, K.D. Somers, E.C. Kohn, and R.R. Perry Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines Surgery 122 1997 372 378 [discussion 378-9]
3. T.W. Moody, J. Chiles, and E. Moody CAI inhibits the growth of small cell lung cancer cells Lung Cancer 39 2003 279 288
4. R. Alessandro, S. Fontana, and M. Giordano Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia J Cell Physiol 215 2008 111 121
5. F.G. Perabo, A. Wirger, and S. Kamp Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 Anticancer Res 24 2004 2869 2877
6. J.K. Wasilenko, C.A. Shinn, and C.R. Willis Carboxyamido-triazole (CAI) - a novel 'static' signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells Leuk Lymphoma 42 2001 1049 1053
7. W.D. Figg, K.A. Cole, and E. Reed Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction Clin Cancer Res 1 1995 797 803
8. E.C. Kohn, E. Reed, and G. Sarosy Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers Cancer Res 56 1996 569 573
9. K.S. Bauer, E.C. Kohn, and R.M. Lush Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model foe simultaneous determination of changing parameters J Pharmacokinet Biopharm 26 1998 673 687
10. W.M. Stadler, G. Rosner, and E. Small Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma-CALGB 69901 J Clin Oncol 23 2005 3726 3732
11. E.C. Kohn, and L.A. Liotta L651582: a novel antiproliferative and antimetastasis agent J Natl Cancer Inst 82 1990 54 60
12. C.C. Felder, A.L. Ma, L.A. Liotta, and E.C. Kohn The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release J. Pharmacol. Exp. Ther. 257 1991 967 971
13. E.C. Kohn, M.A. Sandeen, and L.A. Liotta In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates Cancer Res 52 1992 3208 3212
14. L. Guo, C.Y. Ye, and W.Y. Chen Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumorostatic agent J Pharmacol Exp Ther 325 2008 10 16
15. J.W. Pollard Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 2004 71 78
16. L. Bingle, N.J. Brown, and C.E. Lewis The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies J Pathol 196 2002 254 265
17. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
18. N.J. Goulding The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus Curr Opin Pharmacol 4 2004 629 636
19. E. Ovali, F. Ozdemir, and F. Aydin The effects of dexamethasone on leukemic cells derived from patients with AML J Exp Clin Cancer Res 22 2003 85 89
20. H.J. Eyre, and J.H. Ward Control of cancer chemotherapy-induced nausea and vomiting Cancer 54 1984 2642 2648
21. A. Yano, Y. Fujii, and A. Iwai Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells Clin Cancer Res 12 10 2006 3003 3009
22. M. Banciu, J.M. Metselaar, R.M. Schiffelers, and G. Storm Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue Neoplasia 10 2 2008 108 117
23. H.M.M. Arafa, M.A. Abdel-Hamid, and A.A.K. EI-Khouly Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm Toxicology 222 2006 103 113
24. M.D. Duff, J. Mestre, and S. Maddali Analysis of gene expression in the tumor-associated macrophage J Surg Res 142 2007 119 128
25. W.J. Johnson, K.A. Muirhead, and P.C. Meunier Macrophage activation in rat models of inflammation and arthritis: systemic activation precedes arthritis induction and progression Arthritis Rheum 29 1986 1122 1130
26. F. Balkwill Tumour necrosis factor and cancer Nat Rev 9 2009 361 370
27. T. Hagemann, J. Wilson, and F. Burke Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype J Immunol 176 2006 5023 5032
28. B. Plytycz, A. Pedersen, J. BØgwald, and R. Seljelid In vitro interactions of murine peritoneal macrophages and sarcoma cells Virchows Arch 50 1986 285 292
29. C.H. Lee, C.L. Wu, and A.L. Shiau Toll-like receptor 4 signaling promotes tumor growth J Immunother 33 2010 73 82
30. C.E. Green, T. Liu, and V. Montel Chemoattractant signaling between tumor cells and macrophages regulates cancer cells migration, metastasis and neovascularization PLoS One 4 2009 1 15
31. F. Balkwill Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13 2002 135 141
32. A. Enfissi, S. Prigent, P. Colosetti, and T. Capiod The blocking of capacitative calcium entry by 2-aminoethyl diphenylborate (2-APB) and carboxyamidotriazole (CAI) inhibits proliferation in Hep G2 and Huh-7 human hepatoma cells Cell Calcium 36 2004 459 467
33. O. Mignen, C. Brink, and A. Enfissi Carboxyamidotriazole-induced inhibition of mitochondrial calcium import blocks capacitative calcium entry and cell proliferation in HEK-293 cells J Cell Sci 118 2005 5615 5623
34. M. Karin, and F.R. Greten NF-κB: linking inflammation and immunity to cancer development and progression Nature 3 2005 749 759
35. M. Banciu, J.M. Metselaar, R.M. Schiffelers, and G. Storm Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue Neoplasia 10 2008 108 117
36. A. Jatoi, J.R. Jett, and J. Sloan A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients Support Care Cancer 12 2004 859 863
37. S. Madhusudan, M. Foster, and S.R. Muthuramalingam A phase II study of Etanercept (Enbrel), a tumour necrosis factor-α inhibitor in recurrent ovarian cancer J Clin Oncol 23 2005 5950 5959
38. E.R. Brown, K.A. Charles, and S.A. Hoare A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer Ann Oncol 19 2008 1340 1346
39. Y.M. Ning, J.L. Gulley, and P.M. Arlen Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer Clin Oncol 28 2010 2070 2076
40. G. Mantovani, A. Macci, and C. Madeddu Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia Oncologist 15 2010 200 211
41. H.A. Burris, S.F. Jones, and D. Shipley Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer Cancer Invest 28 2010 408 412
42. W.W. Lin, and M. Karin A cytokine-mediated link between innate immunity, inflammation, and cancer J Clin Investig 117 2007 1175 1183
43. S. Wu, C.M. Boyer, and R.S. Whitaker Tumor necrosis factor alpha as an autocrine and paracrine growth factor for an ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression Cancer Res 53 1993 1939 1944
44. D. Gaiotti, J. Chung, and M. Iglesias Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway Mol Carcinog 27 2000 97 109
45. H. Kulbe, T. Hagemann, and P.W. Szlosarek The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells Cancer Res 65 2005 10355 10362
46. M.J. Chuang, K.H. Sun, and S.J. Tang Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells Cancer Sci 99 2008 905 913
47. Y. Wu, and B.P. Zhou TNF-α/NF-κB/snail pathway in cancer cell migration and invasion Brit J Cancer 102 2010 639 644
48. J.F. Bromberg, M.H. Wrzeszczynska, and G. Devgan Stat3 as an oncogene Cell 98 1999 295 303
49. E.C. Kohn, R. Alessandro, and J. Spoonster Angiogenesis: role of calcium-mediated signal transduction Proc Natl Acad Sci 92 1995 1307 1311
50. Whiteman KR, Johnson H, Xu SQ, et al. Combination therapy with IMGN901 and lenalidomide plus low-dose dexamethasone is highly effective in multiple myeloma xenograft models. AACR 100th Annual Meeting; 2009.
51. S.V. Rajkumar, S. Jacobus, and N.S. Callander Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 2010 29 37
52. J.P. Dutcher, L. Leon, and J. Manola Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study Cancer 104 2005 2392 2399
53. E.A. Johnson, R.S. Marks, and S.J. Mandrekar Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51) Lung Cancer 60 2008 200 207
54. T. Mikkelsen, R. Lush, and S.A. Grossman Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme Invest New Drugs 25 2007 259 263